

A YEAR IN ONCOLOGY


A Review of 2021 Drug Approvals in US, Europe & Japan



Number of Oncology Approvals - US, Europe & Japan

Whilst the global COVID-19 pandemic continued throughout 2021, new oncology drug/indication approvals maintained momentum. Both the US and Japan reflected similar levels of approvals compared to 2020, whilst Europe* saw a higher number of approvals in 2021 vs. 2020.

*The UK will follow EMA regulatory decisions for a period of 2 years following 1st January 2021 - <https://www.gov.uk/guidance/european-commission-ec-decision-reliance-procedure>.




Source: Desk research conducted by the Ipsos Oncology Centre of Expertise, based on publicly available clinical data. Please [CLICK HERE](#) to access the full list of sources.

Please [CLICK HERE](#) to access a glossary of abbreviations/definitions used

TOTAL FDA novel drug approvals/ new indications in oncology ¹	52	TOTAL EMA novel drug approvals/ new indications in oncology ¹	31	TOTAL PMDA novel drug approvals/ new indications in oncology ¹	44
Cancer type receiving the most new indications	Lung	Cancer type receiving the most new indications	Breast	Cancer type receiving the most new indications	Lung
Newly approved biosimilars	0	Newly approved biosimilars	3	Newly approved biosimilars	0
Newly approved generics	0	Newly approved generics	4	Newly approved generics	3

¹NB: Total 2021 approvals *DO NOT* include biosimilars/generics

Key Milestones in Oncology Approvals



Source: Desk research conducted by the Ipsos Oncology Centre of Expertise, based on publicly available clinical data. Please [CLICK HERE](#) to access the full list of sources.

Please [CLICK HERE](#) to access a glossary of abbreviations/definitions used

